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Abstract Asparaginase reduces the levels of asparagine in
blood, which is an essential amino acid for the proliferation
of lymphoblastic malign cells. Asparaginase converts aspara-
gine into aspartic acid and ammonia. The accumulation of
ammonia in the bloodstream leads to hyperammonemia, de-
scribed as one of the most significant side effects of
asparaginase therapy. Therefore, there is a need for
asparaginase formulations with the potential to reduce
hyperammonemia. We incorporated 2 % of therapeutic en-
zyme in albumin-based capsules. The presence of
asparaginase in the interface of bovine serum albumin
(BSA) capsules showed the ability to hydrolyze the aspara-
gine and retain the forming ammonia at the surface of the
capsules. The incorporation of Poloxamer 407 in the capsule
formulation further increased the ratio aspartic acid/ammonia
from 1.92 to 2.46 (and 1.10 from the free enzyme), decreasing
the levels of free ammonia. This capacity to retain ammonia
can be due to electrostatic interactions and retention of ammo-
nia at the surface of the capsules. The developed BSA/
asparaginase capsules did not cause significant cytotoxic ef-
fect on mouse leukemic macrophage cell line RAW 264.7.
The newBSA/asparaginase capsules could potentially be used
in the treatment of acute lymphoblastic leukemia preventing
hyperammonemia associated with acute lymphoblastic leuke-
mia (ALL) treatment with asparaginase.
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Introduction
Asparaginase (EC 3.5.1.1) has been used for the treatment of
malignant hematopoietic diseases in children since 1970.
These diseases include pediatric acute lymphoblastic leuke-
mia (ALL), acute myelocitic leukemia, lymphosarcoma, and
non-Hodgkin lymphomas (Muller and Boos 1998; El-Naggar
et al. 2014). Asparaginase belongs to a family of homologous
amidohydrolases. It catalyzes the hydrolysis of the side chain
amide bond of asparagine, resulting in the formation of
aspartic acid and ammonia (Kumar and Sobha 2012).
For tumor cells, blood serum asparagine is essential for
their growth because they are unable to synthetize their own
asparagine. On the contrary, the growth of normal cells is
independent on its requirement as this amino acid can be syn-
thesized by their own enzyme asparagine synthetase (Wetzler
et al. 2007; El-Naggar et al. 2014). The administration of
asparaginase deprives tumor cells of their extracellular source
of asparagine. This deprivation leads to tumor cell death by
taking advantage of their inability to complete protein
synthesis. Some secondary effects of asparaginase ther-
apy include hyperglycemia, pancreatitis, hepatoxicity,
hypersensitivity reactions, impairment of central nervous
system, hyperammonemia, and occasionally anaphylactic
shock (Fu and Sakamoto 2007; Kumar and Sobha 2012;
Rizzari et al. 2013).
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Albumin/asparaginase capsules prepared by ultrasound
to retain ammonia
Hyperammonemic encephalopathy is a frequently fatal
complication in people treated with asparaginase. It is charac-
terized by increased serum ammonia levels in the absence of
some liver disease that can cause hepatic failure or any other
identifiable cause (Nott et al. 2007; Lyles et al. 2011).
Hyperammonemia was defined as ammonia concentrations
higher than 50 μmol /L and cl in ica l s ign i f ican t
hyperammonemia as ammonia concentrations higher than
100 μmol/L (Heitink-Pollé et al. 2012). Clinical signs of
hyperammonemia can be manifested by several symptoms
affecting the central nervous system such as headache, lethar-
gy, depression, cerebral edema, coma, and even death if the
increase in blood ammonia is not interrupted (Paulides et al.
2013; Nussbaum et al. 2014). To reduce it, it is neces-
sary to reduce exogenous nitrogen intake by protein
restriction and minimize gastrointestinal bleeding.
Nitrogen excretion can also be enhanced by hemodialy-
sis or ammonia-trapping therapy with sodium benzoate
and sodium phenylacetate (Lyles et al. 2011).
Another possible solution to avoid hyperammonemia is the
development of capsules with the capacity to maintain
asparaginase activity after immobilization while capturing
the ammonia resulting from asparaginase activity.
Asparaginase can be immobilized on different supports like
silk fibroin (Zhang et al. 2011) or chitosan (Bahreini et al.
2014) particles, conjugated with sericin protein microparticles
(Zhang et al. 2004), or encapsulated in carboxymethyl konjac
glucomannan–chitosan nanocapsules (Wang et al. 2008). The
enzyme also can be immobilized into a hydrogel matrix made
of polyethylene glycol and bovine serum albumin (BSA)
(Jean-François et al. 1997) or entrapped into a hydrogel
superparamagnetic particles (Teodor et al. 2009). Polyaniline
nanofibers (Ghosh et al. 2012) and fructose polymer levan
(Vina et al. 2001) are also used for asparaginase
immobilization.
These systems focused on the improvement of
asparaginase activity/stability and not on the retention of the
forming ammonia. The development of new systems, with the
capacity to retain the forming ammonia thus reducing the
plasma ammonia concentration resultant from asparaginase
activity, is here explored.
BSA is widely used in the development of systems for drug
delivery because of its abundance, ease of purification, biode-
gradability, low cost, nontoxicity, and nonimmunogenicity
(Elzoghby et al. 2012a). Albumin is used to prepare protein
capsules that can be easily functionalized chemically due to
the reactive groups on their surfaces like amino, thiol, and
carboxylic groups (Loureiro et al. 2014). Due to a high content
of charged amino acids (for example, lysine, arginine, aspar-
tate, and glutamate), the albumin nanoparticles allow electro-
static adsorption of positively or negatively chargedmolecules
(Elzoghby et al. 2012b). Functionalized nanoparticles can be
applied for targeted drug delivery, improving cellular uptake
and alleviating undesired toxic side effects associated with
chemotherapeutic treatments (Loureiro et al. 2015b).
The production of albumin-based nanoparticles can be
achieved using high-intensity ultrasound, which is a high-
energy emulsification method. This method consists in a com-
bination of two acoustic phenomena, emulsification and cav-
itation, and it is used to produce aqueous suspensions of pro-
teinaceous microcapsules (Silva et al. 2012). It was demon-
strated that high shear forces applied to biphasic water/
hydrophobic solvent systems can create a microscopic disper-
sion of the protein solution. In this way, the proteins tend to
migrate to the water/solvent interface, stabilizing the micro-
capsules (Silva et al. 2012; Loureiro et al. 2015b).
In this paper, we report the development of BSA-based
capsules by ultrasound to immobilize asparaginase and eval-
uate their ability to retain the ammonia resulting from
asparaginase activity (Fig. 1). The potential of BSA to form
stable particles by ultrasound and high-pressure homogeniza-
tion was already described by Loureiro et al. (2015b) and
Silva et al. (2012).
To evaluate the capsules’ capacity to retain ammonia, a
new HPLC-MS method was developed, avoiding the amino
acid derivatization process. The forming aspartic acid was
quantified through the new HPLC-MS method and compared
with the ammonia quantified by the Nessler method (Stecher
et al. 1999; Cappelletti et al. 2008).
The systemic application of BSA/asparaginase microcap-
sules by intravenous injection is expected to decrease the am-
monia level below 50 μmol/L, considered the limit value for
hyperammonemia. Normal asparagine levels vary between 40
and 80μM, and the administration of these capsules should be
also capable to obtain a complete asparagine depletion.
However, good results were already obtained by an asparagine
depletion of 0.2 and 0.5 μM (Tong et al. 2014; Appel et al.
2008).
With the BSA/asparaginase formulations, we intend to de-
velop new therapeutic systems for the treatment of ALL,
which will hydrolyze the asparagine to therapeutic levels
while reducing the concentration of ammonia and thus
avoiding hyperammonemia.
Materials and methods
Materials
Asparaginase was obtained from Changzhou Qianhong Bio-
Pharma Co., Ltd. (Jiangsu, China). Asparagine, aspartic acid,
and Poloxamer 407 (Pol407) were obtained from Sigma
(USA). BSA, Dulbecco’s modified Eagle’s medium
(DMEM), glutamine, tetrazolium bromide (MTT), and
Nessler reagent were obtained from Sigma-Aldrich (USA).
Dimethyl sulfoxide (DMSO) was obtained from Fisher
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Scientific (USA) and fetal bovine serum (FBS) from
Biochrom (Berlin, Germany).
Asparaginase enzymatic assay
The hydrolysis reaction of asparagine was performed with
0.001 and 0.0015 g/L of asparaginase and 100 mM of aspar-
agine, at 37 °C, in ultra-pure water. Ultra-pure water was se-
lected as the reactional medium for this assay because 50 mM
Tris buffer affected the quantification of aspartic acid by
HPLC-MS. After 240 min of reaction, the enzyme was
inactivated in an ice-cold bath and removed from the reaction
medium by ultra-centrifugation in Eppendorfs with a mem-
brane cutoff of 5000 Da. After ultra-centrifugation, the mem-
brane was washed with ultra-pure water to prevent amino acid
retention in the membrane. The aspartic acid lost during ultra-
centrifugation was recovered and quantified. The average re-
tention for the aspartic acid was about 5.2 %. The amount of
amino acid entrapped in the filtration membrane was then
considered.
Ammonia quantification by Nessler method
Ammonia quantification was determined by a stopped assay
using Nessler’s reagent. The ammonia produced in 10 μL of
the reactionmixture was determined by the addition of 990 μL
Nessler’s reagent. The optical density of the solution was read
at 436 nm (BioTek®, Synergi MX), and the ammonia concen-
tration was determined on the basis of a standard curve previ-
ously obtained with ammonium sulfate as a standard (Stecher
et al. 1999; Cappelletti et al. 2008).
Aspartic acid quantification by HPLC-MS
without derivatization
Mass spectrometer methodMass spectrometer analysis was
performed on Finnigan LXQ mass spectrometer in a positive
ionization mode. The aspartic acid solution was prepared in
ultra-pure water with 20 % of acetonitrile and then filtered
with 0.2-μm filters. High flow source conditions were opti-
mized for aspartic acid with a flow rate of 5 μL/min. Source
voltage was 4.95 kV, and source current was 0.60 μA. Sheath
gas, aux gas, and sweep gas were 40, 20, and 19.98 arb, re-
spectively. Capillary voltage was 17.77 V, capillary tempera-
ture was 274.88 °C, and the tube lens voltage was 25.01 V.
HPLC-MS method A reverse-phase HPLC system linked
with mass spectrometer was used to isolate aspartic acid.
During methods’ optimization, two columns were tested: the
Kinetex™ 2.6 μm C18 100 Å, LC Column 100 × 4.6 mm
(Phenomenex®) and the Synergi Hydro-RP, 80 Å, 4 μm and
150 × 4.60 mm (Phenomenex®). After optimization, the
Synergi Hydro-RP column with ammonium bicarbonate
0.01 Mwas selected, and the pH adjusted to 6 with formic acid
(A) and acetonitrile (B) as elution solvents. A sample volume of
25 μL was injected with a flow rate of 0.3 mL/min for 20 min.
The gradient program started with 95 % solvent A during the
first 8 min, decreased linearly to 40 % solvent A in the next
7 min, and returned to the initial 95 % during the next 5 min. In
consequence, the solvent B started with 5 % during the first
8 min, increased linearly to 60 % solvent A in the next 7 min,
and returned to the initial 5 % during the next 5 min.
The peak identification was performed through the MS
detector and compared to the elution times obtained when
the amino acids were analyzed separately, in the same condi-
tions. For a more correct calculation of the peak area, the
BBase Peak^ control from Xcalibur program was used. With
this control, it is possible to obtain the peak from each amino
acid individualized by selecting their mass weight.
Effect of BSA on asparaginase stability
To study the effect of BSA on asparaginase stability, several
solutions with different ratios of asparaginase and BSA dis-
solved in PBS were prepared with a protein final concentra-
tion of 10 mg/mL. The solutions were stored at 4 °C, and the
Fig. 1 Scheme of production of
BSA/asparaginase capsules and
retention of ammonia resultant
from asparaginase activity on the
capsules’ surface
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activity was determined over time. Penicillin and streptomy-
cin were added to the BSA/asparaginase solutions to inhibit
the growth of microorganisms which could affect enzyme
activity and stability. The asparaginase activity was deter-
mined weekly for 107 days, on 50 mM Tris pH 8.6, with a
0.001 g/L of asparaginase and 100 mM of asparagine. The
reaction mixture was incubated at 37 °C during 4 h, and the
activity was determined by the Nessler method.
BSA-based capsules prepared by ultrasounds
The BSA, BSA/asparaginase, and BSA/asparaginase/
Pol407capsules were prepared by sonication using
Sonics® Vibra-Cell™. For BSA capsules, BSA was dis-
solved in PBS, pH 7.4, at a final concentration of
10 mg/mL. For BSA/asparaginase capsules, both com-
ponents were dissolved in PBS, pH 7.4, at a final con-
centration of 10 mg/mL with an enzyme percentage of
2 % (w/w). To BSA/asparaginase/Pol407 capsules, the
Poloxamer 407 was added to the previous BSA/
asparaginase solution with a final concentration of
5 mg/mL. The amount of Poloxamer 407 used on the
capsule formulation was based on the work of Loureiro
et al. (2014). The aqueous phase was sonicated with
5 % (v/v) of vegetable oil with a frequency of 20 kHz
and 40 % amplitude of power. The solution was soni-
cated during 6 min with cycles of 10 s (8 s of ultra-
sound pulses on plus 2 s of ultrasound pulses off). After
synthesis, the phase with the capsules was collected by
centrifugation (1000×g during 45 min, at 4 °C) using
centricon tubes (molecular weight cutoff of 100 kDa)
(Amicon Ultra-15, Millipore) (Loureiro et al. 2014). After
separation, the free protein in the aqueous phase was quanti-
fied by the Lowry method (Peterson 1977) in order to deter-
mine the capsule formation efficiency using the formula:
Formation efficiency %ð Þ ¼ Protein½ total− Protein½ free
Protein½ total
 100
ð1Þ
where [Protein]total and [Protein]free is the total concentra-
tion of protein added in formulation and the free concentration
of protein in the aqueous phase solution after centrifugation,
respectively.
Capsule characterization
The emulsions were dispersed in ultra-pure water and ana-
lyzed at 25 °C for their size distribution, polydispersity index
(PDI), and Z-potential. The parameters were determined by
photon correlation spectroscopy, using dynamic light scatter-
ing (Malvern Instruments, Nano-ZS). The values for viscosity
and refractive index were 0.8872 cP and 1.330, respectively.
Each sample was measured in triplicate, and the results are
presented as mean value ± standard deviation.
Cellular viability assay
Cell culture maintenance RAW 264.7 (ATCC® TIB-71™)
cell line (mouse leukemic macrophage cell line) was cultured
in DMEM media, supplemented with 10 % FBS, 1 % gluta-
mine (2 mM), 1 % sodium pyruvate (1 mM), 10 mM HEPES,
and 1 % (v/v) penicillin/streptomycin solution. Cells were
maintained in 75-cm2 tissue culture flasks at 37 °C in a humid-
ified atmosphere with 5 % CO2. The cell culture medium was
renewed twice a week. Subculture was performed when con-
fluence reached values near 80–90 %. For subcultures and plat-
ing, the adherent cells were detached with a scrapper in 5mL of
fresh culture media. The cell suspension was centrifuged for
5 min at 160×g. The supernatant was discarded, and the fresh
medium was added to obtain a new cell suspension. The cell
suspension was loaded in a Neubaeur chamber, and the con-
centration of cells present in the suspension was estimated.
Cell viability assessed by MTTassay Cells were seeded at a
density of 25,000 cells/well on a 96-well tissue culture plate the
day before the experiments. RAW cells were exposed to four
concentrations (25, 50, 100, and 200 μg/mL) of capsules with
asparaginase and to two concentrations of free asparaginase (2
and 4 μg/mL). The two concentrations of free enzyme corre-
spond to the amount of enzyme present in the highest concen-
trations of capsules tested. Cells incubated with DMSO (30 %
of the total volume) and cells without the addition of capsules/
compounds were used as positive and negative controls of cy-
totoxicity, respectively. Raw cells were incubated at 37 °C in a
humidified atmosphere with 5 % CO2. At the end of 24 h of
contact, cell metabolic activity was assessed by the MTT via-
bility assay (Ribeiro et al. 2013). After incubation, the medium
with the capsules and enzyme was removed and 110 μL of
medium with MTT (5 mg/mL) was added to each well, and
cells were further incubated at 37 °C for 2 h. TheMTTsolution
was carefully decanted, and formazan crystals were dissolved
in 110 μL of a DMSO/EtOH (1:1 (v/v)) mixture. Color was
measured with 96-well plate reader at 570 nm in a microplate
reader SpectraMax Plus (Molecular Devices).
Statistical analysis
Data are presented as average standard deviation (SD), n = 3.
Statistical comparisons were performed by one-way ANOVA
with GraphPad Prism 5.0 software (La Jolla, CA, USA).
Tukey’s post hoc test was used to compare all the results
between them, and a Dunnet’s test was used to compare the
results with a specific control. A p value of <0.05 was consid-
ered to be statistically significant.
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Results
BSA effect on asparaginase
Several BSA/asparaginase solutions were prepared to deter-
mine the ratio which conferred higher enzyme stability along
time. Enzyme activity was measured weekly for 107 days by
ammonia quantification using the Nessler method (Stecher et
al. 1999; Cappelletti et al. 2008). The amount of ammonia
produced by the enzyme was determined by comparing the
absorbance of samples at 436 nm with the absorbance of a
calibration curve prepared with ammonium sulfate (Eq. 2).
Absorbance ¼ 0:03046 ammonia½ mMþ 0:03719;
R2 ¼ 0:9976
ð2Þ
Asparaginase half-life times were determined in some
BSA/asparaginase samples. For other samples, the half-life
time was estimated at the end of storage as the final enzyme
activity was higher than half of the initial activity (Table 1).
As illustrated in Table 1, there was an increase in the half-
life time of asparaginase with increasing percentage of BSA in
solution. Comparing all the tested BSA/asparaginase ratios,
the ratio which stabilized the enzyme for a longer period
was the 98 % BSA/2 % asparaginase with an estimated half-
life of 148.95 days. This proportion was chosen for the prep-
aration of BSA/asparaginase capsules by ultrasound.
BSA/asparaginase capsules prepared by ultrasound
Three different types of BSA capsules were prepared by son-
ication: BSA, BSA/asparaginase and BSA/asparaginase/
Pol407. Capsule formation efficiencies were 95.6, 93.9, and
89.8 % for BSA/asparaginase and BSA/asparaginase/Pol407,
respectively.
The ability of capsules to hydrolyze asparagine was
determined by the Nessler method 1 day after synthesis
and compared to the activity of free asparaginase dis-
solved in PBS (Fig. 2). BSA capsules were also tested
for the ability to hydrolyze asparagine although they
did not show any enzymatic activity (data not shown).
There was an increase on asparaginase activity after
immobilization for both tested capsules, with a signifi-
cant increase of 29.73 % for the BSA/asparaginase cap-
sules relatively to the free asparaginase (p value ≤0.01).
The capsules with Poloxamer 407 showed lower
asparaginase activity comparatively to the capsules with-
out Poloxamer 407.
The capsules’ Z-average and PDI were assessed by
photon correlation spectroscopy, whereas laser Doppler
anemometry was employed for Z-potential. Capsules’
physical stability was evaluated over 2 months, by
weekly measurements of capsules’ Z-average, PDI, and
Z-potential, as represented on Fig. 3 for BSA/
asparaginase and BSA/asparaginase/Pol407. For BSA
capsules, their characteristics at day 1 were represented
on Table 2, as they were stable over time.
Generally, all BSA/asparaginase capsules were stable over
time of storage, in respect of size and PDI, with only a signif-
icant difference on BSA/asparaginase capsules’ PDI at day 8
(Fig. 3b, d).
Regarding Z-potential, there was a variation for all
the formulations during storage. BSA/asparaginase/
Pol407 capsules exhibited a slight increase on the net
negative charge of the capsules with storage (Fig. 3c).
For BSA/asparaginase capsules, it was observed a de-
crease on the net negative charge with the storage time,
from −49.10 ± 1.014 to −46.2 ± 0.416 mV (Fig. 3a).
As observed on Table 2, the BSA/asparaginase cap-
sules presented a more negative surface charge when
compared with the BSA capsules due to the addition of
asparaginase to the formulation. The addition of
Poloxamer to the BSA/asparaginase formulation affect-
ed both capsules’ Z-potential and polydispersity.
Table 1 Asparaginase half-life
times of BSA/asparaginase
solutions prepared on PBS
Solution BSA/asparaginase
ratio (%)
Initial activity of asparaginase
(μmol ammonia/mg asparaginase)a
Asparaginase half-life
time (days)
A 0/100 31,950 ± 355 46.70
B 20/80 34,000 ± 220 72.08
C 40/60 43,500 ± 1200 89.18
D 60/40 35,600 ± 700 105.13
E 80/20 48,750 ± 750 120.75b
F 98/2 46,150 ± 800 148.95b
G 100/0 – –
a Enzyme activity was determined at the end of 240 min of incubation, at 37 °C, with 0.001 g/L of asparaginase
and 100 mM asparagine. The absorbances of the solutions after Nessler method were measured at 436 nm and
compared with the absorbance of a calibration curve (Absorbance = 0.03046 [ammonia]mM + 0.03719)
b Estimated half-time of asparaginase
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Optimization of a HPLC-MS method for aspartic acid
quantification
In order to quantify the aspartic acid by HPLC-MS without
derivatization, it was necessary to develop and optimize a
new method. As the Tris buffer affected the quantification of
aspartic acid by HPLC-MS, ultra-pure water was selected as a
reactional medium for asparaginase. When an aspartic acid so-
lution prepared in 50 mM Tris buffer was analyzed, no peaks
were detected both in the positive and negative ionization
mode.
As both asparagine and aspartic acid are present on the
reactionmixture, it was essential to clearly separate the respec-
tive peaks to obtain a correct quantification. An aqueous mix-
ture of asparagine and aspartic was analyzed by HPLC-MS in
order to observe the pattern of peaks corresponding to each
amino acid (data not shown).
A single peak corresponding to the simultaneous elution of
asparagine and aspartic acid was initially observed. The over-
lapping of the peaks does not allow precise aspartic acid quan-
tification. To overcome this drawback, the quantification
method was optimized in order to separate the peaks of both
amino acids. For the analysis, two different columns were
tested: C18 and Hydro-C18 columns. Hydro-C18 columns
achieved the best separation of the peaks, probably due to their
polar endcapped C18 phase that provides extreme retention of
hydrophobic compounds and shows slight polar selectivity.
The mobile phase was also optimized. Water with
0.1 % (v/v) formic acid and acetonitrile were initially
used as eluent; however, this mobile phase was not
suitable for the analysis because it did not allow the
separation of asparagine and aspartic acid (Fig. S1a).
The mobile phase was replaced by ammonium bicarbonate,
pH 6.0 adjusted with formic acid. The eluent and the pH were
chosen based on the pKa of the two amino acids. At pH 6.0,
Fig. 2 Activity of asparaginase immobilized on BSA and BSA/Pol407
capsules prepared by ultrasounds and free asparaginase on PBS. Activity
was determined 1 day after storage at 4 °C. The reaction was performed
with 0.001 g/L of asparaginase and 100 mM of asparagine for 240 min, at
37 °C, in ultra-pure water. Absorbance of the solutions after Nessler
method was measured at 436 nm and compared with the absorbance of a
calibration curve (Absorbance = 0.03046 [ammonia]mM + 0.03719). The
data represents the mean ± SD from three independent experiments. Data
were analyzed by one way-ANOVA: p value ≤0.05 (asterisk), p value
≤0.01 (circle), compared to the results obtained for free asparaginase
Fig. 3 Characterization of BSA/
asparaginase capsules (a, b) and
BSA/asparaginase/Pol407
capsules (c, d), during storage at
4 °C. a, c Z-potential; b, d
Z-average and PDI. The data
represents the mean ± SD from
three independent experiments.
Data were analyzed by one
way-ANOVA: p value ≤0.05
(asterisk), p value ≤0.01 (circle),
p value ≤0.001 (diamond), p
value ≤0.0001 (square),
compared to the results obtained
at day 1
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asparagine and aspartic acid have different electrical charge
which helped the separation of the two peaks during the chro-
matography. To increase the peaks’ resolution, the analysis
was performed in high flow conditions, with a flow rate of
0.3 mL/min.
After column, flow rate, and elution gradient optimization,
the chromatographic analysis was performed using the col-
umn Hydro-C18, a flow rate of 0.3 mL/min, and ammonium
bicarbonate (A) and acetonitrile (B) as eluents. The first peak
with a retention time of 4.13min corresponded to aspartic acid
and the second one, with a retention time of 4.60 min, to
asparagine (Fig. S1b).
Using this approach, it was possible to identify and
separate both asparagine and aspartic acid amino acids
without derivatization, when mixed in the same aqueous
solution.
BSA/asparaginase capsules’ capacity to retain ammonia
In order to study the ability of capsules with asparaginase
to retain ammonia, the products of asparagine hydrolysis,
aspartic acid, and ammonia were simultaneously quantified
after asparaginase activity and compared. The asparaginase
concentration used in the capsules was 0.001 g/L, while
for the free asparaginase, a concentration of 0.0015 g/L
was used. For this concentration of free enzyme, the
quantified aspartic acid and ammonia were within the
range of values determined for the capsules. The BSA
capsules were not tested regarding their ability to retain
ammonia since they are not, by themselves, able to
hydrolyze asparagine.
The ammonia was quantified by the Nessler method, while
the aspartic acid was quantified against an aspartic acid stan-
dard curve (Eq. 3) using the new, optimized HPLC-MS meth-
od (Table 3).
Peak area ¼ 583946 aspartic acid½ mM
R2 ¼ 0:9625
ð3Þ
The main objective of this work was the development
of capsules with the ability to hydrolyze asparagine
while retaining the forming ammonia. The ammonia re-
tention on the capsules’ interface results from the elec-
trostatic interaction between the positively charged
ammonia and the superficial negatively charged groups
of the capsules.
The ratio between the two products is related with the abil-
ity of BSA/asparaginase capsules to retain ammonia. For
aspartic acid/ammonia ratios higher than 1, the capsule had
the capacity to retain the ammonia resulting from the
asparaginase activity.
Generally, for all the BSA/asparaginase capsules, a higher
aspartic acid concentration relative to the ammonia concentra-
tion was observed, with BSA/asparaginase/Pol407 capsules
showing the highest aspartic acid/ammonia ratio of 2.46
(Table 3).
The free asparaginase also retains some ammonia,
although it was not significant when compared with
the capsules.
Evaluation of BSA/asparaginase capsules’ cytotoxicity
by MTT assay
To assess the potential cytotoxic effect of the BSA-based cap-
sules, mouse leukemic macrophage RAW 264.7 cells, which
are positive for expression of asparagine synthetase (Suzuki et
al. 2002), were used as a model of general cytotoxicity. The
cells were exposed to four concentrations of capsules (25, 50,
100, and 200 μg/mL) and two concentrations of asparaginase
(2 and 4 μg/mL). The concentrations of asparaginase corre-
spond to the amount of enzyme present in the two highest
concentrations of capsules. After 24 h of incubation, the met-
abolic activity of the cells was evaluated with the MTT assay
(Fig. 4).
Analyzing Fig. 4, the BSA/asparaginase capsules did
not show any significant toxic effect for any of the
tested concentration. These capsules presented cell via-
bility higher than 93.2 ± 5.31 %. When Poloxamer 407
was added to this formulation, the capsules’ toxic effect
increased for all the concentrations. For BSA capsules
without asparaginase, only the highest concentration
displayed significant levels of cytotoxicity, with a via-
bility lower than 80 %. However, the incorporation of
asparaginase and Poloxamer 407 on the interface of
BSA capsules decreased the BSA toxic effect observed
for the concentration of 200 μg/mL BSA capsules. The
free asparaginase also presented some cytotoxicity for
both tested concentrations.
Table 2 Physical properties of
BSA-based capsules 1 day after
synthesis
BSA-based capsulesa Z-average (nm) PDI Z-potential (mV)
BSA 183.47 ± 23.38 0.4297 ± 0.038 −28.8 ± 0.9
BSA/asparaginase 227.30 ± 4.60 0.52 ± 0.036 −49.10 ± 1.01
BSA/asparaginase/Pol407 232.67 ± 15.15 0.31 ± 0.066 −3.03 ± 0.26
a BSA-based capsules stored at 4 °C
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Discussion
In order to determine the BSA/asparaginase ratio that con-
ferred higher stability to the enzyme when immobilized,
asparaginase half-life times of the solutions were determined.
The proportion that most stabilized the enzyme was 98 %
BSA/2 % asparaginase, and this ratio was chosen for the prep-
aration of BSA/asparaginase capsules. This stabilizing effect
of high concentrations of BSAwas already reported for other
proteins like acetylcholinesterase, ovalbumin, and lysozyme
(Sah 1999; Nasseau et al. 2001).
The ability of BSA/asparaginase capsules prepared by ul-
trasounds to hydrolyze asparagine into aspartic acid and am-
monia was determined. The capsules with Poloxamer 407
showed lower asparaginase activity comparatively to the cap-
sules without Poloxamer 407. This could be due to the steric
effect of the Poloxamer 31 that could hinder the asparaginase
and thus reduce the amount of substrate available near the
enzymes’ catalytical center.
The BSA-based capsules were characterized regarding
size, polydispersity, and net charge. The more negative Z-po-
tential of BSA/asparaginase/Pol407 capsules after 2 months
could be due to a rearrangement of Poloxamer 407, leading
to desorption of some surfactant molecules from the capsules’
surface. This slight variation on the Z-potential after storage,
from −49 to −45 mv, was not significant to consider a desta-
bilization of the particles. The desorption of Poloxamer 407
will expose more asparaginase and BSA molecules on the
capsules’ surface, making the Z-potential more negative.
As observed on Table 2, the BSA/asparaginase capsules
presented a more negative surface charge when compared
with the BSA capsules due to the addition of asparaginase to
the formulation. Asparaginase has an isoelectric point of 4.9
(Ehrman et al. 1971) and is deprotonated at pH 7.4, acquiring
a net negative charge. The more negative Z-potential could be
justified by the addition of asparaginase to the formulation and
its localization at the surface of the capsules.
The addition of Poloxamer to the BSA/asparaginase for-
mulation affected both capsules’ Z-potential and polydispersi-
ty, resulting in a more homogeneous population. The less neg-
ative net charge results from the coating of the BSA/
asparaginase capsules by the nonionic surfactant, which
shields’ the surface charge.
In order to prove the capsules’ capacity to retain ammonia,
an HPLC-MS method for the quantification of asparagine and
aspartic acid was optimized. The best results were obtained
using Hydro-C18 column and, as a mobile phase, acetonitrile
and ammonium bicarbonate, pH 6.0 adjusted with formic ac-
id. Hydro-C18 columns achieved the best separation of the
peaks, probably due to their polar endcapped C18 phase that
provides extreme retention of hydrophobic compounds and
shows slight polar selectivity. The ammonium bicarbonate
and the pH were chosen based on the pKa of the two amino
acids. At pH 6.0, asparagine and aspartic acid have different
electrical charge which helped to separate the two components
during the chromatography (Fig. S1).
The main goal of the present work was the development of
formulation with the ability to hydrolyze asparagine while
Fig. 4 Relative viability of RAW 264.7 (macrophage cell line from
leukemic mouse) evaluated with the MTT assay, after 24-h incubation
in medium containing BSA, BSA/asparaginase, and BSA/asparaginase/
Pol407 capsules and two concentrations of free asparaginase. The free
asparaginase concentrations correspond to the amount of enzyme
present in the highest capsules’ concentrations. Cells incubated with
culture medium were used as negative control and cells incubated with
30 % DMSO as positive control of cytotoxicity. Data were determined in
relation to the life control. Results are the mean ± SD of triplicate of three
independent experiments. Statistical significant differences from the
control are indicated as follows: p value ≤0.05 (asterisk), p value ≤0.01
(circle)
Table 3 Study of the capacity of
BSA/asparaginase capsules to re-
tain ammonia
Samples Z-potential
(mV)
Aspartic acida
(mM)
Ammoniab
(mM)
Ratio (aspartic
acid/ammonia)
BSA/asparaginase −43.90 ± 0.79 52.52 ± 1.95 27.35 ± 0.43 1.92
BSA/asparaginase/Pol407 −1.75 ± 0.43 37.99 ± 0.96 15.61 ± 0.17 2.46
Asparaginase (0.0015 g/L) −9.42 ± 2.83 44.91 ± 3.91 40.91 ± 4.75 1.10
a Aspartic acid quantified by HPLC-MS comparing the peak area with the calibration curve: Peak area = 583,946
[aspartic acid]mM
b Ammonia quantified by Nessler method considering the calibration curve: Absorbance = 0.03046
[ammonia]mM + 0.03719
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retaining the forming ammonia. To evaluate the ability of the
BSA/asparaginase-based capsules, the amount of forming am-
monia and aspartic was quantified and compared.
Ammonia retention on the capsules’ surface results from
the electrostatic interaction between the positively charged
ammonia and the superficial negatively charged groups of
the capsules. If the capsules’ ability to retain ammonia was
only related to electrostatic interactions, more negative formu-
lations such as BSA/asparaginase will retain ammonia more
efficiently. Nevertheless, the formulation that retained more
ammonia was the BSA/asparaginase/Pol407 capsule.
The free asparaginase also retains some ammonia, although
it was not significant when compared with the amount of
ammonia retained by the capsules. The capacity of free
asparaginase to retain ammonia is related to the protonation
state of asparaginase. At pH 7.4, asparaginase is deprotonated
(Baran et al. 2002), and thus, it has some capacity to retain the
positively charged ammonia.
The simultaneous quantification of aspartic acid and am-
monia confirmed the capsules’ interfacial capacity to retain
the forming ammonia. However, it seems that the BSA/
asparaginase capsules’ ability to retain ammonia was not only
due to electrostatic interaction between the negative charges
on the capsules’ interface and the ammonia but could be also
related with the entrapment of ammonia in the surface of the
capsules.
To determine the cytotoxic effect of the BSA-based cap-
sules, RAW 264.7 cell line was used as a model. The RAW
264.7 is a monocyte macrophage cell line obtained from mu-
rine leukemia. This cell line was chosen because it is a cell
from the immune system and has the capacity to synthesize
asparagine as they express the asparagine synthetase enzyme
(Suzuki et al. 2002). Any signs of cytotoxicity will be due to
the composition of the capsules and not to the anti-leukemic
activity of asparaginase.
Despite that the RAW 264.7 cell line is able to produce its
asparagine, the free asparaginase had some cytotoxicity.
Besides the hydrolytic activity over asparagine, asparaginase
also presents some glutaminase activity which could affect
cell viability at some extent.
Although some marginal cytotoxicity, though not relevant,
was noted, studies indicate that BSA/Pol407 particles are safe
to use even in vivo with animals not developing any adverse
reaction or losing weight or compromising survival (Loureiro
et al. 2015a).
Generally, the developed BSA/asparaginase capsules did
not induce significant cytotoxicity in the tested cell line.
In the present work, a newHPLC-MSmethod for the quan-
tification of aspartic acid without a derivatization step was
successfully developed. Higher protective effect of BSA for
asparaginase was achieved in a proportion of 98 % BSA/2 %
asparaginase. This proportion was selected for the capsules’
preparation by ultrasounds.
The new asparaginase immobilization systems were stable
over time and showed a higher capacity to retain ammonia
than the free asparaginase. This capacity seems not only relat-
edwith the capsules’ net charge but also with an entrapment of
ammonia in the capsules’ interface. Moreover, all the devel-
oped BSA-based capsules did not display significant cytotox-
icity to RAW 264.7 cell line. In the future, the capsules’ anti-
leukemic potential combined with their ability to retain am-
monia will be evaluated.
The interfacial capacity of the BSA-asparaginase-based
capsules, here presented, to retain ammonia, is of particular
interest. The developed systems have the potential to be used
as new therapeutic formulations for the treatment of ALL as
they maintain the asparaginase activity while retaining ammo-
nia and thus avoiding hyperammonemia.
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